Emergency treatment with levetiracetam or phenytoin in status epilepticus in children-the EcLiPSE study: study protocol for a randomised controlled trial
Mark D Lyttle, Carrol Gamble, Shrouk Messahel, Helen Hickey, Anand Iyer, Kerry Woolfall, Amy Humphreys, Naomi EA Bacon, Louise Roper, Franz E Babl, Stuart R Dalziel, Mary Ryan, Richard E Appleton
TRIALS | BMC | Published : 2017
BACKGROUND: Convulsive status epilepticus (CSE) is the most common life-threatening neurological emergency in childhood. These children are also at risk of significant morbidity, with acute and chronic impact on the family and the health and social care systems. The current recommended first-choice, second-line treatment in children aged 6 months and above is intravenous phenytoin (fosphenytoin in the USA), although there is a lack of evidence for its use and it is associated with significant side effects. Emerging evidence suggests that intravenous levetiracetam may be effective as a second-line agent for CSE, and fewer adverse effects have been described. This trial therefore aims to deter..View full abstract
Awarded by NIHR HTA
Awarded by Medical Research Council
The EcLiPSE study is funded by the NIHR HTA under grant agreement 12/127/134. The study is co-sponsored by Alder Hey Children's NHS Foundation Trust and the University of Liverpool. The study funder and co-sponsors play no part in study design, data collection or analysis, writing of the report; or the decision to submit for publication; the responsibility for these activities lies with the TMG.